SGLT-2 inhibitors and most GLP-1 receptor agonists demonstrated cardiovascular superiority and reduction of cardiovascular and overall mortality. These results stand as a turning point in the management of diabetes, shifting the focus from controlling glucose levels to mastering the extra-glycemic effects of these new drugs. This narrative review will discuss recent CVOT with focus on SGLT-2 inhibitors and GLP-1 receptor agonists to distinguish relevant patients' characteristics as potential predictors for therapeutic efficacy. It will also examine their efficacy and safety, the differences in their cardiovascular and renal benefits, aiming to convey clinical suggestions for everyday practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.metabol.2019.154045DOI Listing

Publication Analysis

Top Keywords

sglt-2 inhibitors
12
glp-1 receptor
12
receptor agonists
12
inhibitors glp-1
8
differential indication
4
indication sglt-2
4
inhibitors versus
4
versus glp-1
4
agonists patients
4
patients established
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!